FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208701766> ?p ?o ?g. }

• W3208701766 endingPage "3480" @default.
• W3208701766 startingPage "3480" @default.
• W3208701766 abstract "3480 Background: SPARC (Secreted Protein Acidic and Rich in Cysteine) is overexpressed in many cancers including breast, prostate, lung, brain, head-and-neck, and kidney. We have previously shown that SPARC expression appeared to correlate with response to nanoparticle albumin-bound (nab) paclitaxel (Abraxane, ABX) in head-and-neck cancer patients, and increase in SPARC suggested improved response to ABX in tumor models. To further define the role of SPARC, a cell line engineered to overexpress SPARC was used to test whether SPARC overexpression would result in increased albumin binding and increased response to ABX in vivo. Methods: Recombinant human SPARC was expressed and purified using HEK 293 cells. Biologic activities of rhSPARC were characterized by testing cytotoxicity against human cancer cell lines and normal rat hepatocytes, angiogenesis in a HUVEC tube formation assay, and affinity for albumin in a solid phase binding assay with Alexa 488 labeled BSA binding to rhSPARC immobilized onto PVDF. To examine the effect of SPARC overexpression on tumor response to ABX, SPARC cDNA was subcloned into an expression vector and stable SPARC overexpressing lines of PC3 prostate cancer cells were generated by calcium phosphate transfection and G418 selection. The PC3 SPARC overexpressor (HN104) and WT PC3 were grown as xenografts in vivo and examined for response to ABX (30 mg/kg, qdx5, N=5). Results: Purified rhSPARC had a N-terminal sequence identical to native human SPARC, expected amino acid composition, and mature, low mannose glycosylation. In the HUVEC tube formation assay, rhSPARC was pro-angiogenic at 10 µg/mL and anti-angiogenic at 100 µg/mL. rhSPARC was noncytotoxic against HT29, MX-1, HepG2, and normal rat hepatocytes at all dose levels. The SPARC albumin binding assay revealed a pattern of saturable and specific binding with an estimated Kd of 700 µM. The HN104 SPARC overexpressing xenograft exhibited enhanced response to ABX with T-C of 36 days compared with the parent WT PC3 xenograft with T-C of 25 days (p Conclusions: rhSPARC exhibited an affinity for albumin at physiologic concentrations, potentially leading to targeting of nanoparticle albumin-bound drugs in vivo. Exogenous rhSPARC stimulated angiogenesis (tube formation) in vitro, supporting the role of SPARC in tumor angiogenesis and invasiveness. The SPARC overexpressing prostate cancer PC3 xenograft exhibited enhanced response to ABX relative to WT PC3, supporting the hypothesis that SPARC overexpression could lead to enhanced anti-tumor effect of nanoparticle albumin-bound drugs." @default.
• W3208701766 created "2021-11-08" @default.
• W3208701766 creator A5023123170 @default.
• W3208701766 creator A5035601887 @default.
• W3208701766 creator A5040852712 @default.
• W3208701766 creator A5059615305 @default.
• W3208701766 creator A5078711459 @default.
• W3208701766 creator A5087960295 @default.
• W3208701766 creator A5091376104 @default.
• W3208701766 date "2007-05-01" @default.
• W3208701766 modified "2023-09-28" @default.
• W3208701766 title "SPARC overexpression enhances sensitivity to nab-paclitaxel in vivo" @default.
• W3208701766 hasPublicationYear "2007" @default.
• W3208701766 type Work @default.
• W3208701766 sameAs 3208701766 @default.
• W3208701766 citedByCount "2" @default.
• W3208701766 countsByYear W32087017662013 @default.
• W3208701766 crossrefType "journal-article" @default.
• W3208701766 hasAuthorship W3208701766A5023123170 @default.
• W3208701766 hasAuthorship W3208701766A5035601887 @default.
• W3208701766 hasAuthorship W3208701766A5040852712 @default.
• W3208701766 hasAuthorship W3208701766A5059615305 @default.
• W3208701766 hasAuthorship W3208701766A5078711459 @default.
• W3208701766 hasAuthorship W3208701766A5087960295 @default.
• W3208701766 hasAuthorship W3208701766A5091376104 @default.
• W3208701766 hasConcept C105795698 @default.
• W3208701766 hasConcept C121608353 @default.
• W3208701766 hasConcept C126322002 @default.
• W3208701766 hasConcept C131075544 @default.
• W3208701766 hasConcept C150903083 @default.
• W3208701766 hasConcept C153911025 @default.
• W3208701766 hasConcept C160160445 @default.
• W3208701766 hasConcept C181199279 @default.
• W3208701766 hasConcept C185592680 @default.
• W3208701766 hasConcept C207001950 @default.
• W3208701766 hasConcept C2776125364 @default.
• W3208701766 hasConcept C2777292972 @default.
• W3208701766 hasConcept C2781460891 @default.
• W3208701766 hasConcept C33923547 @default.
• W3208701766 hasConcept C502942594 @default.
• W3208701766 hasConcept C54009773 @default.
• W3208701766 hasConcept C54355233 @default.
• W3208701766 hasConcept C55493867 @default.
• W3208701766 hasConcept C60962613 @default.
• W3208701766 hasConcept C71924100 @default.
• W3208701766 hasConcept C81885089 @default.
• W3208701766 hasConcept C86803240 @default.
• W3208701766 hasConceptScore W3208701766C105795698 @default.
• W3208701766 hasConceptScore W3208701766C121608353 @default.
• W3208701766 hasConceptScore W3208701766C126322002 @default.
• W3208701766 hasConceptScore W3208701766C131075544 @default.
• W3208701766 hasConceptScore W3208701766C150903083 @default.
• W3208701766 hasConceptScore W3208701766C153911025 @default.
• W3208701766 hasConceptScore W3208701766C160160445 @default.
• W3208701766 hasConceptScore W3208701766C181199279 @default.
• W3208701766 hasConceptScore W3208701766C185592680 @default.
• W3208701766 hasConceptScore W3208701766C207001950 @default.
• W3208701766 hasConceptScore W3208701766C2776125364 @default.
• W3208701766 hasConceptScore W3208701766C2777292972 @default.
• W3208701766 hasConceptScore W3208701766C2781460891 @default.
• W3208701766 hasConceptScore W3208701766C33923547 @default.
• W3208701766 hasConceptScore W3208701766C502942594 @default.
• W3208701766 hasConceptScore W3208701766C54009773 @default.
• W3208701766 hasConceptScore W3208701766C54355233 @default.
• W3208701766 hasConceptScore W3208701766C55493867 @default.
• W3208701766 hasConceptScore W3208701766C60962613 @default.
• W3208701766 hasConceptScore W3208701766C71924100 @default.
• W3208701766 hasConceptScore W3208701766C81885089 @default.
• W3208701766 hasConceptScore W3208701766C86803240 @default.
• W3208701766 hasLocation W32087017661 @default.
• W3208701766 hasOpenAccess W3208701766 @default.
• W3208701766 hasPrimaryLocation W32087017661 @default.
• W3208701766 hasRelatedWork W1970750693 @default.
• W3208701766 hasRelatedWork W1971458206 @default.
• W3208701766 hasRelatedWork W1986542607 @default.
• W3208701766 hasRelatedWork W2012293141 @default.
• W3208701766 hasRelatedWork W2026430894 @default.
• W3208701766 hasRelatedWork W2056333789 @default.
• W3208701766 hasRelatedWork W2073709607 @default.
• W3208701766 hasRelatedWork W2157126713 @default.
• W3208701766 hasRelatedWork W2384056100 @default.
• W3208701766 hasRelatedWork W2389301143 @default.
• W3208701766 hasRelatedWork W2416996427 @default.
• W3208701766 hasRelatedWork W2478844847 @default.
• W3208701766 hasRelatedWork W2588248925 @default.
• W3208701766 hasRelatedWork W2897853339 @default.
• W3208701766 hasRelatedWork W2901113762 @default.
• W3208701766 hasRelatedWork W2956081254 @default.
• W3208701766 hasRelatedWork W2995497419 @default.
• W3208701766 hasRelatedWork W3029720750 @default.
• W3208701766 hasRelatedWork W3032887617 @default.
• W3208701766 hasRelatedWork W3180776963 @default.
• W3208701766 hasVolume "67" @default.
• W3208701766 isParatext "false" @default.
• W3208701766 isRetracted "false" @default.
• W3208701766 magId "3208701766" @default.
• W3208701766 workType "article" @default.